STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
Conditions: Vulvar Squamous Cell Carcinoma Interventions: Procedure: Surgery; Other: Active Surveillance Sponsors: Canadian Cancer Trials Group; Australia New Zealand Gynaecological Oncology Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Oropharynx (OPX) Biomarker Trial
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Metastatic Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
Conditions: Recurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma Interventions: Drug: INQOVI (decitabine and cedazuridine); Drug: Nivolumab Sponsors: Case Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy Interventions: Drug: paclitaxel polymer micelles and cisplatin combined with Cadonilimab Sponsors: Sun Jing Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Conditions: Urologic Neoplasms; Urogenital Neoplasms; Male Urogenital Diseases; Penile Cancer; Penile Squamous Cell Carcinoma; Locally Advanced Penile Carcinoma Interventions: Drug: Carboplatin/Paclitaxel; Drug: Pembrolizumab; Procedure: Partial or total penectomy with inguinal and/or pelvic lymph node dissection Sponsors: The Netherlands Cancer Institute; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.
Conditions: De-escalated Radiotherapy; Head and Neck Cancer Interventions: Radiation: Continuous, hyperfractionated, accelerated radiotherapy(CHART) Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY
Conditions: Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes Interventions: Drug: Tegafur Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions: Neoadjuvant Therapy; Esophageal Squamous Cell Carcinoma Interventions: Drug: anlotinib; Radiation: Thoracic radiotherapy Sponsors: Army Medical Center of PLA Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
Conditions: Metastatic Cancer; NSCLC Stage IV; Non-small Cell Lung Cancer Stage IV; Small Cell Lung Cancer Metastatic; Solid Tumor; Clear Cell Renal Cell Carcinoma Metastatic; Urothelial Carcinoma Bladder; Cutaneous Malignant Melanoma; Castration-resistant Prostate Cancer; Prostate Cancer Metastatic; TNBC - Triple-Negative Breast Cancer; Breast Cancer Stage IV; Colon Cancer Stage IV; MSI-H Cancer; Cervical Cancer Stage IV; Endometrial Cancer Stage IV; Mismatch Repair-Deficient Endometrial Endometrioid Adenocarcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Tissue Collection Sponsors: Mayo Clinic Not yet...
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Conditions: Advanced or Metastatic NRAS-mutant Melanoma Interventions: Drug: Naporafenib; Drug: Dacarbazine; Drug: Temozolomide; Drug: Trametinib Sponsors: Erasca, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma Interventions: Drug: SP-002; Drug: Vismodegib Sponsors: Stamford Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma; Sintilimab; Radiotherapy; Concurrent Chemoradiotherapy; Immunonutrition Interventions: Radiation: Radiotherapy; Drug: Programmed Cell Death Protein 1 Inhibitor; Dietary Supplement: Immunonutrition support Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Concurrent Programmed Cell Death Protein 1 Inhibitor and Radiotherapy With Immunonutrition Support for in Unresectable Esophageal Squamous Cell Carcinoma Patients
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma; Sintilimab; Radiotherapy; Concurrent Chemoradiotherapy; Immunonutrition Interventions: Combination Product: Sintilimab + radiotherapy + enteral nutritional emulsion (TPF-T) Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Dermatoscopy Guided Resection for Skin Cancer
Conditions: Basal Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Surgical Margin Interventions: Device: Dermatoscopy Sponsors: Region Örebro County Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Interventions: Drug: Adebrelimab; Drug: Apatinib; Drug: Tegafur Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
